1. CURRICULUM VITAE
Name: Terry Adrian Potter
Administrative Position Associate Vice Chancellor
Faculty Rank: Professor
Present Address: Office of the Provost
University of Colorado Denver
1380 Lawrence St., 14th Floor
P.O. Box 173364
Denver, Colorado 80217-3364
Email terry.potter@ucdenver.edu
Education: 1976; B.Sc. (Hons), Monash University, Melbourne, Australia
1977-1980; Ph.D., University of Melbourne, Melbourne, Australia
Professional Positions: Training and Faculty
6/16/99 – Present Professor, Dept of Immunology, University of Colorado Denver |
Anschutz Medical Campus, CO.
7/1/92 – 6/15/99: Associate Faculty Member, Dept of Medicine, National Jewish Medical
and Research Center (NJMRC; now National Jewish Health), and
Associate Professor Dept of Immunology, University of Colorado Health
Sciences Center (UCHSC), Denver, CO.
10/1/88 - 6/30/92: Assistant Faculty Member, Dept of Medicine, NJMRC, and Assistant
Professor, Dept of Microbiology & Immunology, UCHSC Denver, CO.
7/1/86 - 9/30/88: Assistant Professor, Dept of Pathology, Albert Einstein College of
Medicine (AECOM), Bronx, NY.
5/1/82 - 6/30/86: Associate, Dept of Pathology, AECOM, Bronx, NY.
5/1/80 - 4/30/82: Postdoctoral research fellow at Merck, Sharp and Dohme Research
Laboratories, Rahway, NJ.
Professional Positions: Administrative
1/1/12 – Present Associate Vice Chancellor for Academic Planning, University of Colorado
Denver | Anschutz Medical Campus, CO.
6/17/14 – 10/1/15 Acting Dean, Graduate School University of Colorado Denver | Anschutz
Medical Campus, CO.
9/1/09 – 12/31/11 Asst Vice Chancellor University of Colorado Denver | Anschutz Medical
Campus, CO
10/01/07 – 8/31/09 Special Assistant to the Provost, University of Colorado Denver |
Anschutz Medical Campus, CO
02/01/07 – 09/30/08 Assistant Vice President for Academic Affairs, NJMRC
7/1/99 – 9/1/06 Director, Graduate Program Dept of Immunology, UCHSC, Denver, CO
10/1/96 – 6/1/00 Co-Director, Immunology Program, University of Colorado Cancer Center

2. Administrative Experience
Associate Vice Chancellor Academic Planning
• Oversee periodic (every 5-7 years) program review of all Schools, Colleges, Departments,
Institutes and Centers at the University of Colorado Denver | Anschutz Medical Campus.
• Assist Deans, faculty and administrative staff develop proposals (academic plans and budgets)
for new degrees for submission to the Board of Regents.
• Assist Deans, faculty and administrative staff develop proposals (academic plans and budgets)
for new Centers for submission to the Chancellor.
Achievements: Conducted an average of fifteen external reviews each academic year and
assisted the academic units develop three-year implementation plans. Assisted in the
development and approval of seventeen new degree programs and fifteen new centers
Acting Dean, Graduate School
• Oversee 73 graduate programs enrolling 2,200 students at both campuses
• Oversight for the school’s annual budget ($8M) – planning and allocation
• Oversight for all (approximately 300) postdoctoral fellows, including provision of career
development activities.
Achievements:
Implemented major reorganization of Graduate School staff and their duties.
Reorganized postdoctoral office into a Career Development Office for students as well as
postdoctoral fellows.
Assistant Vice Chancellor for Academic Effectiveness
• Coordinator and principal author of the self study prepared for the accreditation by the Higher
Learning Commission (HLC).
• Plan and co-ordinate the site visit by the HLC team.
• Serve as Institutional Liaison Officer to the HLC
Achievements: First accreditation of the University of Colorado Denver | Anschutz Medical
Campus as a consolidated University. The accreditation was approved for 10 years without any
issues of concern or designated for follow up.
Special Assistant to the Provost:
• Chaired a faculty committee that developed rules and policies for the newly consolidated
Graduate School comprised of Graduate programs at both the Denver and Anschutz Medical
Campuses.
• Assist in planning activities to develop Mission Vision Values statements for the newly
consolidated University of Colorado Denver | Anschutz Medical Campus.
• Assist in the planning, data collection, analysis and writing of the University of Colorado Denver
| Anschutz Medical Campus Strategic Plan
Achievements: Approval and adoption of the initial : (i) rules of the Graduate School; (ii)
Mission, Vision Values statements and (iii) Strategic plan; for the newly consolidated University
of Colorado Denver | Anschutz Medical Campus

3. Fellowship Awards:
2/01/77 - 3/31/80: Commonwealth (Aust. Govt.) University Graduate Scholarship.
5/01/82 - 4/30/84: Fellowship from the Cancer Research Institute Inc..
5/01/85 - 4/30/88 Special fellowship from the Leukemia Society of America.
7/01/91 - 6/30/96 Scholar of the Leukemia Society of America
Research Support (1986-2008):
American Heart Association;
National Institutes of Health (NIH)
Principal Investigator on investigator initiated R01 grants 1988-
2008;
Project leader on NIH Program Project (P01) Grants;
Principal Investigator on a NIH NIAID T32 award supporting 4
postdoctoral fellows and 5 predoctoral students.
Teaching and Mentorship Awards:
May 2000 Dean’s Mentoring Award from the UCHSC Graduate School
May 2001 National Jewish Medical & Research Center “Teacher of the Year”
May 2002 National Jewish Medical & Research Center “Teacher of the Year”
Faculty Service and Committee Activities:
1990 to 1999: NJMRC - Biohazard Committee (Chair).
1990 to 2009 UCHSC - Immunology Grad. Program Admissions Committee
1990 to 2006 UCHSC - Immunology Grad. Program Steering Committee
2005 - 2009 NJMRC, Member Promotions and Appointments Committee
Review and Referee Activities
Journal Reviews:
Adhoc reviewer for multiple journals including, Journal of
Immunology.Nature, J. Exp. Med
Grant Reviews:
1989 – 2008: Adhoc member, NIH Immunobiology and related study
sections; New Initiatives for HIV Vaccines Study Section, (NIH)
1995-1999: US Army Breast Cancer Research Grants.
1997 Member, Review Panel for FDA (Center for Biologicals Division)
1998 Member, Review Panel for CDC
Institutional Reviews
2010 – Present: Peer Reviewer for the Higher Learning Commission

4. Teaching Activities:
(A) Graduate Courses
1984 - 1986 Lecturer, graduate student course in Immunogenetics, Sue Golding
Graduate School, Albert Einstein College of Medicine, Bronx, NY.
1986 - 1988 Co-Director and Lecturer, graduate student course in Immunogenetics,
Albert Einstein College of Medicine, Bronx,NY.
1989 - 2006 Lecturer at University of Colorado School of Medicine in the following
courses: (* denotes currently or previous course director)
Immunology *
Advanced Immunology *
Special Topics in Immunology
Cell Biology of the Immune System *
Special Topics in Immunology
Lecturer in Advanced Molecular Genetics
Special Techniques in Immunology *
Special Topics in Tumor Immunology
Special Topics in Signaling in the Immune System
Science as a Profession” (“ethics and development” class) *
2006 – Present Advanced Immunology (IMMU 7662)
Small Group teaching in MD program: First year students Blood &
Lymph Block
(B) Undergraduate Courses
2001 – 2006 Course Director “Immunology” (MCDB 4300) University of Colorado
Boulder Campus
(C) Ph. D. Thesis Mentor
Cindy Knall, Ph.D. candidate, 1989 - 1994
Pam Smith, M.D. Ph.D. candidate 1992 - 1997
Heather Zwickey, Ph.D. candidate 1994 - 1998
Kristie Grebe, Ph. D. candidate 2000 – 2004
Raedun Clarke Ph. D. candidate 2003- 2007
Sandra Thiemann, Ph.D. candidate 2004-2009
(D) Thesis Advisory Committees
Dianne Metcalf, Ph.D. candidate, 1989 -1991.
Ken Gollob, Ph.D. candidate, 1989 - 1991.
Paul Nash, Ph. D. candidate, 1991 - 1994. (Chairman)
Bill Wheat, Ph. D. candidate, 1991 - 1993. (Chairman)
John Donahue, Ph. D. candidate, 1991 - 1993 (Chairman)
Jill Callahan, Ph. D. candidate, 1991- 1993
Chris Pleiman, Ph. D. candidate, 1992 - 1994 (Chairman)
Jeff Seibel, Ph. D. candidate, 1992 - 1995
Leslie Miller, Ph. D. candidate, 1992 - 1995 (Chairman)
Lily Pao, Ph. D. candidate, 1993 - 1996
Michael Princiotta, Ph. D. candidate, 1994 - 1998 (Chairman).
Marc Hertz, Ph. D. candidate 1996 - 1998
Chia-Chi Kua, Ph. D. candidate 1995 – 1999 (Chairman)
Elizabeth Zahradka, Ph. D. candidate 1996 - 1999
Rance Berg, Ph. D. candidate 1997 - 1999
John Stolpa, Ph. D. candidate 1997 – 2000 (Chairman).
Ben Frieberg, Ph. D. candidate 1998 – 2000 (Chairman).
Andrew Diamond, Ph. D. candidate 1997 – 2000
Herbert Gelhaus, Ph. D. candidate 2000 – 2004
Eli Boritz, Ph. D. candidate 2001 – 2004.
Cristen Hoyt, Ph. D. candidate 2001 – 2004
Brian Turner, Ph. D. candidate 2001 – 2004

5. David Mills, Ph. D. candidate 2001 – 2003(Chairman).
Jenny Terry Ph. D. candidate 2002 – 2005 (Chairman).
Joe Delli Ph. D. candidate 2003 – 2006
Lisa Davis Ph. D. candidate 2003– 2007
Ph. D. candidate 2003 – 2008 (Chairman).
Rachel McMahan Ph. D. candidate 2003 – 2008 (Chairman).
Kristen Morris Ph. D. candidate 2003 – 2007 (Chairman).
Andrea Vondracek Ph. D. candidate 2004 – 2009
Leila Nazemi Ph. D. candidate 2004 – 2008 (Chairman)
Yibing Wang Ph. D. candidate 2004 – 2008
Kira Rubtsova Ph.D. candidate 2006 – 2009 (Chairman)
Jason Oh Ph. D. candidate 2006 – 2010
Ryan Bjordahl Ph. D. candidate 2007 – 2011
Amber Ortiz Ph. D. candidate 2014 – Present

6. Bibliography
(excluding Abstracts)
1. Sandrin, M.S., Potter, T.A., Morgan, G.M. and McKenzie, I.F.C.: Detection of mouse
alloantibodies by rosetting with protein-A coated sheep red cells. Transplantation 26:126-130,
1978.
2. McKenzie, I.F.C., Potter, T.A., Shen, F.W. and Boyse, E.A.: Mouse lymphocyte alloantigens in
"Inbred and Genetically Defined Strains of Laboratory Aimals". (Eds. P.L. Altman, and D.D.
Katz). F.A.S.E.B. Biological Handbooks, Section 37, 1978.
3. McKenzie, I.F.C. and Potter, T.A.: Murine lymphocyte surface antigens. Adv. Immunol.
27:179, 1979.
4. Potter, T.A., Watt, S.M., Burgess, A.W. and McKenzie, I.F.C.: Characterization of surface
alloantigens of murine neutrophils. Immunogenetics 8:151, 1979.
5. Thompson, C.H., Potter, T.A., McKenzie, I.F.C. and Parish, C.R.: Phenotype of the DTH
suppressor cell. Immunology 40:87, 1980.
6. Potter, T.A., McKenzie, I.F.C., Morgan, G.M. and Cherry, M.: Murine lymphocyte alloantigens.
I. The Ly-6 locus. J. Immunology 125:541, 1980.
7. Potter, T.A., Morgan, G.M. and McKenzie, I.F.C.: Murine lymphocyte alloantigens. II. Ly-7
locus. J. Immunology 125:546, 1980.
8. Potter, T.A., Hogarth, P.M. and McKenzie, I.F.C.: FACS analysis of T cell alloantigen
expression. Eur. J. Immunol. 10:898, 1980.
9. Hogarth, P.M., Potter, T.A., Cornell, D. and McKenzie, I.F.C.: The description of a monoclonal
Lyt1.1 antibody. J. Immunol. 125:1618, 1980.
10. Potter, T.A. and McKenzie, I.F.C.: Further description of the Ly-4 locus. J. Immunogenetics
8:15, 1981.
11. Potter, T.A. and McKenzie, I.F.C.: Identification of new murine lymphocyte alloantigens:
Antisera prepared between C57L, 129 and related strains define new loci. Immunogenetics
12:351, 1981.
12. Mottram, P.L., Potter, T.A., Cornell, D., McKenzie, I.F.C. and Miller, J.F.A.P.: Serological
analysis of macrophage surface alloantigens. Cell. Immunology 59:151, 1981.
13. Potter, T.A., Hogarth, P.M. and McKenzie, I.F.C.: Ly-15 a new murine lymphocyte
alloantigenic locus. Transplantation 31:339, 1981.
14. Potter, T.A., Hansen, T.H., Habbersett, R., Ozato, K. and Ahmed, A.: Flow microflurometric
analysis of H-2L expression. J. Immunol. 127:580, 1981.
15. Hansen, T.H., Ozato, K., Potter, T.A. and Sachs, D.: Monoclonal antibodies to H-2Ld antigens.
In: "Monoclonal Antibodies and T Cell Hybridomas", (Eds. G.J. Hammerling, U. Hammerling
and J.F. Kearney), Elseiver/North Holland, 1981.
16. Boyd, H.C., Potter, T.A., Rajan, T.V., Zmijewski, C.M. and McKearn, T.J.: A rodent Class I
MHC determinant is shared among many species. Immunogentics 18:183, 1983.
17. Potter, T.A., Palladino, M., Wilson, D. and Rajan, T.V.: Epitopes on H-2Dd somatic cell
mutants recognized by cytotoxic T cells. J. Exp. Med. 158:1061, 1983.

7. 18. Rajan, T.V., Halay, E.D., Potter, T.A., Evans, G.A., Seidman, J.G. and Margulies, D.H.: H-2
hemizygous mutants from a heterozygous cell line: Role of mitotic recombination. EMBO. J.
2:1537, 1983.
19. Skelly, R.R., Potter, T.A. and Ahmed, A.: Lymphocytes antigens and receptors. In: "Molecular
Immunolgy", (Eds., M.Z. Atassi, C.J. van Oss, and D.R. Absolom), Marcel Dekker, Inc., New
York, 1984.
20. Potter, T.A., Boyer, C., Schmitt-Verhaulst, A.M., Golstein, P. and Rajan, T.V.: Exprerssion of
H-2Db on the cell surface in the absence of detectable β-2 microglobulin. J. Exp. Med. 160:317,
1984.
21. Bluestone, J.A., Potter, T.A., Chattersee-Hasrouni, S. and Rajan, T.V.: CTL recognize different
determinants from those defined serologically on Ld somatic cell mutants. J. Immunol.
133:1168, 1984.
22. Lillehoj, E.P., Walsh, W.D., Potter, T.A., Lee, D.R. and Hansen, T.H.: Chemical and serological
definition of two unique D-region encoded molecules in the wild-derived mouse strain
B10.GAA37. J. Immunol. 133:3138, 1984.
23. Potter, T.A., Zeff, R.A., Schmitt-Verhulst, A.M. and Rajan, T.V.: Molecular analysis of an EL4
cell line which expresses H-2Db but not H-2Kb or β-2m. Proc. Natl. Acad. Sci. USA 82:2950,
1985.
24. Frankel, W., Potter, T.A., Rosenberg, N., Lenz, J. and Rajan, T.V.: Retroviral insertional
mutagenesis of a target allele in a heterozygous murine cell line. Proc. Natl. Acad. Sci. USA
82:6600-6664, 1985.
25. Greenblatt, H.C., Potter, T.A. and Rosenstreich, D.: Genetic control of natural resistance to
trypanosoma rhodesiense: Transfer of resistance with bone marrow or spleen cells. J. Infect.
Dis. 151:911, 1985.
26. Martinko, J.M., Anderson, S.J. and Potter, T.A.: A murine cell line defective in expression of
several class I molecules. Immunogenetics 23:64-66, 1986.
27. Potter, T.A., Zeff, R.A., Frankel, W. and Rajan, T.V.: Mitotic recombination betwen
homologous chromosomes generates H-2 somatic cell mutants in vitro. Proc. Natl. Acad. Sci.
USA. 84:1634-1637, 1987.
28. Potter, T.A., Frankel, W., Zeff, R.A. and Rajan, T.V.: Spontaneous deletion at the β-2m locus:
Evidence for site specific genomic rearrangement. J. Immunol. 138:1270-1274, 1987.
29. Rembecki, R.M., Bennett, M., Kumar, V. and Potter, T.A.: Expression of hemopoietic
histocompatibility antigens on H-2 loss variants of F1 hybrid lymphoma cells: Evidence
consistent with transgene regulation. J. Immunol. 138:2734-2738, 1987.
30. Potter, T.A., Bluestone, J. and Rajan, T.V.: Role of the α-3 domain of class I H-2 molecules in
CTL recognition. J. Exp. Med. 166:956-966, 1987.
31. Connolly, J.M., Potter, T.A., Wormstall, E.M. and Hansen, T.H.: The Lyt-2 molecule recognizes
residues in the class I α-3 domain in allogeneic cytotoxic T cell responses. J. Exp. Med.
168:325-341, 1988.
32. Frankel, W., Potter, T.A. and Rajan, T.V.: Effect of proviral insertion on transcription of the
murine B2mb gene. J. Virology 63:2623-2628, 1989.
33. Bluestone, J.A. and Potter, T.A.: T cell clones and monoclonal antibodies: Immunologic probes
of major histocompatibility complex class I molecules, Chem. Immunol. (formerly Progress in
Allergy) 46:23-48, 1989.

8. 34. Potter, T.A., Rajan, T.V., Dick, R.F. and Bluestone, J.A.: Substitution at residue 227 of H-2
class I molecules abrogates recognition by CD8-dependent cytotoxic T lymphocytes. Nature
337:73-75, 1989.
35. Connolly J.M., Hansen, T.H., Ingold, A.L. and Potter, T.A. Recognition by CD8 on cytotoxic T
lymphocytes is ablated by several substitutions in the class I α3 domain: CD8 and the T cell
receptor recognize the same class I molecule. Proc. Natl. Acad. Sci. USA. 87:2137-2141, 1990.
36. Vitiello, A., Potter, T.A. and Sherman, L.A. The role of β2 microglobulin in peptide binding by
class I molecules. Science 250: 1423-1426, 1990.
37. Ingold, A.L., Landel, C., Knall, C., Evans, G.A. and Potter, T.A. Co-Engagement of CD8 with
the T cell receptor is required for Negative Selection. Nature 352: 721-723, 1991.
38. Clark, M.R., Campbell, K.S., Kazlauskas, A, Hertz, M., Potter, T.A., Pleiman, C. and Cambier,
J.C. The B cell antigen receptor complex: Association of Ig-α and Ig-β with distinct cytoplasmic
effectors. Science 258: 123-126, 1992.
39. Knall, C. Ingold, A. and Potter T.A. Analysis of coreceptor versus accessory molecule function
of CD8 as a corelate of exogenous peptide concentration. Molecular Immunology 31: 875-883,
1994.
40. Knall, C.Smith P.A. and Potter T.A. CD8 independent CTL require co-engagement of CD8 and
the TCR for phosphotidylinositol hydrolysis, but CD8-independent CTL do not and can kill in
the absence of phosphotidylinositol hydrolysis. International Immunolgy 7:995-1004, 1995.
41. Drevets, D.A., Sawyer, R.T., Potter, T.A. and Campbell, P.A. Listeria monocytogenes infects
human endothelial cells by two distinct mechanisms. Infection and Immunity 63:4268-4276,
1995.
42. Zwickey, H. and Potter, T.A. Peptide epitopes from non-cytosolic Listeria monocytogenes caa
be presented by major histocompatibility complex class I molecules. Infection and Immunity
64:1870 - 1872, 1996.
43. Hamelmann, E. Oshiba, A., Paluh, J. Bradley, K., Loader, J., Potter, T.A., Larsen, G. and
Gelfand, E.W. Requirement for CD8+ T cells in the development of bronchial
hyperresponsiveness in a murine model of airway sensitization. J. Exp Med. 183:1719-1729,
1996.
44. Cook, J.L., Potter, T.A., Bellgrau, D. and Routes, B.A. E1A oncogene expression in target cells
induces cyto;ytic susceptibility at a post-recognition stage in the interaction with killer
lymphocytes. Oncogene 13:833-842, 1996.
45. Shen, L., Potter, T.A. and Kane, K.P. The Glu227-Lys substitution in the acidic loop of MHC
class I a3 domain distinguishes low -avidity CD8 coreceptor and avidity-enhanced CD8
accessory functions. J. Exp Med. 184:1671-1683, 1996.
46. Sawyer, R.T., Drevets D.A., Campbell, P.A. and Potter, T.A. Infection of the macrophage cell
line J774 by Listeria monocytogenes is mediated by internalin J. Leuk. Biol. 60:603-610, 1996.
47. Lappin, M.R., Burney, D.P., Dow, S.D. and Potter, T.A. Polymerase chain reaction for the
detection of Toxoplasma gondii in aqueous humor of cats. Am. J. Vet. Res. 57:1589-1593,
1996.
48. Smith, P.A., Brunmark. A., Jackson, M. and Potter, T.A. Some alloreactive CD8 indepenedent
CTL recognize MHC molecules in the absence of peptide. J. Exp Med. 185: 1023-1034, 1997.
49. Dow, S. and Potter, T.A. Expression of bacterial superantigens by mammalian cells can
stimulate T lymphocytes in vitro and inflammation in vivo. J. Clin Invest. 99:2616-2624, 1997.

9. 50. Dow, S.W., Elmslie, R.E., Roche, L., Gorman, C., Willson, A. and Potter, T.A. Local tumor
immunotherapy with DNA encoding bacterial superantigen and GM-CSF induces tumor
regression and prolongs survival in dogs with spontaneous malignant melanoma. J. Clin Invest.
101:2406-2411, 1998.
52. Smith, P.A. and Potter, T.A. Alloreactive T Cells which do not Require TCR and CD8
Coengagement are Present in Naive Mice and Contribute to Graft Rejection. J. Immunol.
160:5382-5389, 1998.
53. Vella, A.T., Dow, S., Potter, T.A., Kappler, J. and Marrack, P. Cytokine induced survival of
activated T cells in vitro and in vivo. Proc Natl Acad Sci U S A 95:3810-3815, 1998.
54. Wheeler, C.J., Chen J-Y., Potter, T.A. and Parnes, J.R. Mechanisms of CD8β-mediated T cell
response enhancement: Interaction with MHC class I/β2-microglobulin and functional coupling
to TCR/CD3. J. Immunol. 160:4199-4207, 1998.
55. Burney, D.P., Chavkin,M.J., Dow, S.W., Potter, T.A., and Lappin, M.R. Polymerase chain
reaction for the detection of Toxoplasma gondii within aqueous humor of experimentally-
inoculated cats. Vet Parasitol. 79:181-186, 1998.
56. Zwickey, H.L.and Potter,T.A. Antigen Secreted from Noncytosolic Listeria monocytogenes is
Processed by the Classical MHC Class I Processing Pathway. J. Immunol. 162:6341-6350, 1999.
57. Zwickey, H.L.and Potter,T.A. Lymphocytes:Precursor frequency. In Encylopedia of Life
Sciences, MacMillan Press London, 1999.
58. Dow, S.W., Liggitt, D.L., Fradkin, L., Willson, A.P., Heath, T.D. and Potter, T.A. Lipid-DNA
complexes induce potent immune activation of innate immune responses and antitumor
immunity activity when administered intravenously. J. Immunol 163:1552-1561, 1999.
59. Dow, S.W., Schwarze, J., Heath, T.H., Potter, T.A. and Gelfand, E.W. Systemic and local
interferon-γ gene delivery to the lungs for treatment of allergen induced airway hypersensitivity
in mice. Human Gene Therapy 10:1905-1914, 1999.
60. Dow S.W., Elmslie R.E., Fradkin L.G., Liggitt D.H., Heath T.H., Willson A.P. and Potter T.A.
Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established
lung metastases. Human Gene Therapy 10:2961-2972, 1999.
61. Dow, S.W., Roberts, A., Vyas, J., Rodgers, J., Rich, R.R., Orme, I. and Potter, T.A. .
Immunization With f-Met Peptides Induces Immunity Against Mycobacterium tuberculosis.
Tubercle & Lung Disease 80: 5-13, 2000.
62. Routes, J. M., Ryan, S., Clase, A., Miura, T., Kuhl, A., Potter, T. and Cook, J. E1A Oncogene
Expression in Tumor Cells Enhances Killing by TNF-Related Apoptosis Inducing Ligand
(TRAIL) J. of Immunol. 165: 4522-4527, 2000.
63. Walsh, P., Gonzalez, R., Dow, S., Elmslie, R., Potter, T., Glode, L.M., Baron, A.E., Balmer, C.,
Easterday, K., Allen, J. and Rosse, P. A phase I study using direct combination DNA injections
for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Trial.
Hum. Gene Ther. 11:1355-1368, 2000.
64. Kedl R.M., Jordan M., Potter T.A., Kappler J., Marrack P. and Dow S. CD40 Stimulation
accelerates deletion of tumor specific CD8+ T cells in the absence of tumor-antigen
immunization. PNAS 98:10811-10816, 2001
65. Potter T.A.,, Freiberg B., Grebe K. and Kupfer A. Supramolecular Activation Clusters are
Formed on CD8+ T cells Following Coengagement of the TCR and CD8. PNAS 98: 12624-
12629, 2001.

10. 66. Grebe KM and Potter TA. Enumeration, Phenotyping, and Identification of Activation Events in
Conjugates Between T cells and Antigen-Presenting Cells by Flow Cytometry. Science STKE.
149 :PL14. 2002
67. Grebe KM, Clarke, R. and Potter, TA. Ligation of CD8 leads to Apoptosis of Thymocytes that
have not Undergone Positive Selection. PNAS 101:10410-10415, 2004.
68. Miura, T., Cook, J.L., Potter, T.A., Ryan, S.,and Routes, J.M. The interaction of adenovirus E1A
with p300 family members modulates cellular gene expression to reduce tumorigenicity. J Cell
Biochem. Mar 1;100(4):929-40, 2007 .
69. Cook, L., Miyahara, N., Jin, N., Wands, J.M., Taube, C., Roark, C.L., Potter, T.A., Gelfand,
E.W., O'Brien, R.L., and Born, W.K. Evidence that CD8+ dendritic cells enable the
development of gammadelta T cells that regulate airway hyperresponsiveness. J.Immunol.,
181:309-318, 2008.
70. Young, R.M. , Hardy, I.R., Clarke, R.L., Lundy, N., Pine, P., Turner, B.C., Potter, T.A. and
Refaeli, Y. Mouse models of non-hodgkins lymphoma reveal Syk as an important therapeutic
target. Blood 113:2508-2516, 2009
71. Clarke, R.L., Thiemann S., Refaeli Y., Werlen G., and Potter T.A. "A New Function for LAT
and CD8 During CD8-Mediated Apoptosis that is Independent of T Cell Receptor Signal
Transduction" Eur. J. Immunol. 39: 1619-31, 2009.
72. Schmidt, R.L., Filak, H.C., Lemon, J.D., Potter, T.A. and Lenz, L.L. A LysM and
SH3-Domain Containing Region of the Listeria monocytogenes p60 Protein
Stimulates Accessory Cells to Promote Activation of Host NK Cells. PLoS
Pathog 7(11): e1002368. doi:10.1371/journal.ppat.1002368